Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Eltrombopag→

Eltrombopag Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
496775-61-2
Molecular formula
C25H22N4O4
Molecular weight
442.47 g/mol
Drug class
Thrombopoietin Receptor Agonist
Mechanism of action
Thrombopoietin Receptor Agonists
Indications / reported uses
  • Anemia, Aplastic
  • Purpura, Thrombocytopenic, Idiopathic
  • patients with myelodysplastic syndrome (MDS)
  • thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy
  • thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy

Sources: FDA product labels (openFDA) · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Eltrombopag Environmental Risk Assessment (ERA) (the Eltrombopag ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.